Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for NovaBay Pharmaceuticals (NBY) over the last 15 years, with Q3 2025 value amounting to $31000.0.

  • NovaBay Pharmaceuticals' Other Accumulated Expenses fell 7129.63% to $31000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $31000.0, marking a year-over-year decrease of 7129.63%. This contributed to the annual value of $85000.0 for FY2024, which is 6288.21% down from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' Other Accumulated Expenses stood at $31000.0, which was down 7129.63% from $85000.0 recorded in Q2 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Other Accumulated Expenses registered a high of $480000.0 during Q1 2023, and its lowest value of $31000.0 during Q3 2025.
  • Its 5-year average for Other Accumulated Expenses is $236105.3, with a median of $229000.0 in 2023.
  • Per our database at Business Quant, NovaBay Pharmaceuticals' Other Accumulated Expenses surged by 36341.46% in 2021 and then plummeted by 7129.63% in 2025.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Other Accumulated Expenses stood at $309000.0 in 2021, then skyrocketed by 45.95% to $451000.0 in 2022, then tumbled by 49.22% to $229000.0 in 2023, then plummeted by 62.88% to $85000.0 in 2024, then plummeted by 63.53% to $31000.0 in 2025.
  • Its last three reported values are $31000.0 in Q3 2025, $85000.0 for Q2 2025, and $100000.0 during Q1 2025.